Search clinical trials for: MRD-

Total 250 results

Chr Hansen
University of Copenhagen

Completed

Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children (PiP-C)

Dental Caries

Denmark
Amgen

Recruiting

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

B-precursor Acute Lymphoblastic Leukemia

United States
University of British Columbia
AstraZeneca; Ozmosis Research Inc.

Recruiting

SCION: SABR and Checkpoint Inhibition Of NSCLC (SCION)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Lung Cancer Stage I | Lung Adenocarcinoma, Stage I | Lung Squamous Cell Carcinoma Stage I

Canada
Geneplus-Beijing Co. Ltd.

Not yet recruiting

The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer

Ovarian Cancer

China
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
Nanfang Hospital of Southern Medical University

Unknown

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia | B-Cell Lymphoblastic Leukemia

United States
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Colorectal Cancer | Liver Metastases | Minimal Residual Disease | Liquid Biopsy | Stage IV Colorectal Cancer | ctDNA
Jiangsu Cancer Institute & Hospital

Recruiting

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Non-small Cell Lung Cancer

China
Suzhou Municipal Hospital

Recruiting

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Cervical Cancer

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Acute Myeloid Leukemia | Measurable Disease

China
Zhejiang University

Recruiting

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL

B-ALL

China
Adaptive Biotechnologies
Stanford University

Recruiting

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
Seoul National University Hospital
Amgen

Recruiting

Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

Minimal Residual Disease | Pediatric ALL, B Cell

Korea, Republic of
University of British Columbia
Amgen

Terminated

Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant (OZM-097)

Minimal Residual Disease | B-cell Adult Acute Lymphoblastic Leukemia | Stem Cell Leukemia

Canada
Beijing Immunochina Medical Science & Technology...

Unknown

Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation

Leukemia

China
Nanfang Hospital of Southern Medical University
Guangzhou First People's Hospital; Second Affiliated Hospital, Sun Yat-Sen... and other collaborators

Unknown

The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML

Acute Myeloid Leukemia | Minimal Residual Disease | Granulocyte Colony-stimulating Factor

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia | Complete Hematologic Remission (CHR) | Persistent/Recurrent Minimal Residual Disease (MRD)

Italy
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (FIL_GAZEBO)

Follicular Lymphoma

Italy
University of Oklahoma

Not yet recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Androgen Deprivation Therapy | Locally Advanced Prostate Cancer

United States
ImmunoGen, Inc.
Jazz Pharmaceuticals

Active, not recruiting

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Germany, France, Spain, Italy, United Kingdom
Zhujiang Hospital

Recruiting

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

Hepatocellular Carcinoma Resectable

China
Shanghai Chest Hospital

Recruiting

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Non-small Cell Lung Cancer | Minimal Residual Disease | Immunotherapy | Anti-angiogenesis

China
Hospital General de Mexico

Recruiting

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Acute Lymphoblastic Leukemia, in Relapse | Chemotherapeutic Toxicity | Minimal Residual Disease

Mexico
First Affiliated Hospital of Zhejiang University
Xiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaborators

Recruiting

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Hematologic Malignancy | Stem Cell Transplant Complications

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Acute Myeloid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia (LAL2317)

Acute Lymphoid Leukemia | Philadelphia Chromosome-Negative B-Cell Precursor

Italy
Karolinska University Hospital
Nordic MDS Group

Recruiting

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

Myelodysplastic Syndromes | Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts | Mixed Myelodysplastic/Myeloproliferative Disease

Sweden
University of Jena
Ludwig-Maximilians - University of Munich

Terminated

Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia, Adult

Germany
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
Adaptive Biotechnologies

Active, not recruiting

The clonoSEQ® Watch Registry

Multiple Myeloma | Chronic Lymphocytic Leukemia | Non-hodgkin Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell

United States
Qingdao Central Hospital
Yake Biotechnology Ltd.

Unknown

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-Cell | Minimal Disease, Residual

China
Boehringer Ingelheim

Completed

Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers

Asthma | Rhinitis, Allergic, Perennial

Korea, Republic of
University of Alabama at Birmingham
Miltenyi Biotec, Inc.

Active, not recruiting

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

Hematopoietic Stem Cell Transplantation

United States
University of Rochester

Recruiting

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome (MRD)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic Lymphoma Group

Active, not recruiting

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

CLL

Netherlands, Denmark
Zhujiang Hospital

Not yet recruiting

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

Recurrence | Surgery | Hepatocellular Carcinoma Resectable

China
Second Affiliated Hospital of Wenzhou Medical University

Recruiting

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

Epithelial Ovarian Cancer

China
National Research Center for Hematology, Russia

Recruiting

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Russian Federation
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate (LAL1913)

Secondary | De Novo | Untreated Philadelphia Positive Acute Lymphoblastic Leukemia | Low-dose Corticosteroids Pretreatment

Italy
University of California, Irvine
Natera, Inc.; Taiho Pharmaceutical Co., Ltd.

Recruiting

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Colorectal Cancer | Colon Adenocarcinoma

United States
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Allogeneic Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia | Tyrosine Kinase Inhibitor

China
National Cancer Center, Japan
H.U. Group Research Institute G.K.

Recruiting

Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study

HER2-positive Breast Cancer

Japan
Institute of Hematology & Blood Diseases Hospital

Recruiting

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Multiple Myeloma

China
SWOG Cancer Research Network
National Cancer Institute (NCI); Janssen, LP

Recruiting

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Multiple Myeloma

United States, Canada
Peking University People's Hospital

Recruiting

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Gastrointestinal Stromal Tumors

China
Peking University People's Hospital

Recruiting

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

Gastrointestinal Stromal Tumors | Minimal Residual Disease

China

Search clinical trials for: MRD-

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations